Checkpoint Therapeutics, Inc.
NASDAQ:CKPT
Overview | Financials
Company Name | Checkpoint Therapeutics, Inc. |
Symbol | CKPT |
Currency | USD |
Price | 3.44 |
Market Cap | 165,575,800 |
Dividend Yield | 0% |
52-week-range | 1.38 - 4.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. James F. Oliviero III, C.F.A., CFA |
Website | https://www.checkpointtx.com |
An error occurred while fetching data.
About Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD